StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Tuesday ...
Hosted on MSN2mon
Immedica to buy Marinus Pharmaceuticals for $151mGlobal rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m. Marinus is a commercial-stage pharmaceutical company ...
Hosted on MSN1mon
Marinus Pharmaceuticals CEO Scott Braunstein sells $167,530 in stockScott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and Exchange Commission.
MARINUS PHARMACEUTICALS ($MRNS) is expected to release its quarterly earnings data on Tuesday, March 11th after market close, per Finnhub. Analysts are expecting ...
The company has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50. A number of hedge funds and ...
Scott Braunstein, Chairman and CEO of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), recently executed several stock transactions, according to a filing with the Securities and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback